NCT07787247招募中不适用
Pilot Study: Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Subject Study Completion
研究概览
简要总结
Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor. The hypothesis is that continuous monitoring of key aspects of patient physiology and activity coupled to rigorous telemedicine-performed examination has the potential to detect MG worsening which requires change in treatment with the benefit of avoiding need for hospitalization or emergent therapy. This study is to evaluate the reliability of the technology and patient compliance to the monitoring program
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has the capacity to understand and sign an informed consent form
- •≥18 years old
- •Diagnosed with acquired autoimmune MG based on clinical syndrome and seropositivity for MG associated autoantibodies (AChR binding, MuSK, or LRP4 antibodies), and/or a decremental response on repetitive nerve stimulation, positive single fiber electromyography (EMG) or positive edrophonium test
- •Subject has been previously evaluated in a face-to-face clinical encounter at participating study site or referral site within the prior 3 years
- •Primary language is English, or equivalent level of English language fluency
- •Required disease severity range previously judged by the Investigator. MGFA class 1-4a within 3 years of diagnosis without other chronic medical conditions, which compromise participation.
- •Having MG-ADL score above 2 upon entrance to study
- •Patients considered by study PI not to require hospitalization at time of entrance
- •The patient has internet capability and a smart phone compatible with the apps required by the study.
排除标准
- •Disease Specific Exclusion Criteria
- •Inability to comply with study protocol for monitoring
- •Current MGFA Severity Class IVb or V, or patients in remission with MGFA Class 0
- •Any significant medical/psychiatric condition that, in the opinion of the Investigator, may interfere with interpretation of subject evaluation(s) or protocol compliance
- •Any disorder that could limit ability to assess myasthenia gravis specific deficits (not including planned or recent thymectomy)
- •Pregnancy, based on the evaluator's judgment, if the subject is deemed not safe to undergo evaluation or comply with study visit requirements.
- •Lack of effective internet connection or ability to use study telemedicine station and monitors
- •Home environment prevents use of study equipment
- •Likelihood of leaving DC, Maryland, or Virginia area in year after initiation of study
- •Subject is already participating in a research study -
结局指标
主要结局
Subject Study Completion
时间窗: 12 months
Proportion of subjects complete the 12-month study
Datasets retrieved from study assessments
时间窗: 12 months
Proportion of assessments provide data sets that can be analyzed
次要结局
- Subject Satisfaction(12 months)
- MG-ADL and MG-CE(12 months)
- Fitbit correlation(12 months)
- Hospital Anxiety and Depression Scale(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG CrisisMyasthenia GravisNCT07411963Centre Hospitalier Universitaire de Nice30
尚未招募
不适用
Talquetamab in Patients With Refractory Generalized Myasthenia GravisMyasthenia Gravis (MG)NCT07499323First Affiliated Hospital of Chongqing Medical University2
招募中
不适用
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)Generalized Myasthenia GravisNCT07570589Centre Hospitalier Universitaire de Nice50
招募中
1 期
Study of Aritinercept in Patients With Generalized Myasthenia GravisNCT07596901Aurinia Pharmaceuticals Inc.81
尚未招募
不适用
Proteomic Changes in Patients With Myasthenia Gravis and RavulizumabNCT07337395Fondazione Policlinico Universitario Agostino Gemelli IRCCS24